{"id":40931,"date":"2025-08-01T07:00:36","date_gmt":"2025-08-01T11:00:36","guid":{"rendered":"https:\/\/www.ncqa.org\/?page_id=40931"},"modified":"2026-01-30T07:06:54","modified_gmt":"2026-01-30T12:06:54","slug":"cardiovascular-monitoring-for-people-with-cardiovascular-disease-and-schizophrenia-smc","status":"publish","type":"page","link":"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/cardiovascular-monitoring-for-people-with-cardiovascular-disease-and-schizophrenia-smc\/","title":{"rendered":"Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)"},"content":{"rendered":"<p><span class=\"TextRun SCXW108358917 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW108358917 BCX0\">The percentage of persons 18\u201364 years of age with schizophrenia or schizoaffective disorder and cardiovascular disease, who had an LDL-C test during the measurement period.<\/span><\/span><span class=\"EOP SCXW108358917 BCX0\" data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<h2>Why It Matters<\/h2>\n<p><b><span data-contrast=\"auto\">Compared to the general population, individuals with schizophrenia or schizoaffective disorder are at significantly higher risk of developing cardiovascular disease <\/span><\/b><span data-contrast=\"auto\"><sup>(1)<\/sup>. This disparity is believed to be driven in part by a higher occurrence of dyslipidemia in people with serious mental illness <sup>(2)<\/sup>. For example, use of certain atypical antipsychotic drugs is associated with increased low-density lipoprotein (LDL) cholesterol\u2014 a marker that indicates elevated risk for coronary heart disease <sup>(3)<\/sup>.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559738&quot;:180,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Among patients with co-occurring schizophrenia and metabolic disorders, rates of nontreatment were 62.4% for hypertension and 88.0% for hyperlipidemia. Atypical antipsychotic medications elevate the risk of metabolic conditions, relative to typical antipsychotic medications <sup>(4)<\/sup>.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559738&quot;:180,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<h2><span data-teams=\"true\">Historical Results \u2013 National Averages<\/span><\/h2>\n","protected":false},"excerpt":{"rendered":"<p>The percentage of persons 18\u201364 years of age with schizophrenia or schizoaffective disorder and cardiovascular disease, who had an LDL-C test during the measurement period.\u00a0 Why It Matters Compared to the general population, individuals with schizophrenia or schizoaffective disorder are at significantly higher risk of developing cardiovascular disease (1). This disparity is believed to be [&hellip;]<\/p>\n","protected":false},"author":45,"featured_media":0,"parent":733,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page.php","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-40931","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC) - NCQA<\/title>\n<meta name=\"description\" content=\"Assesses adults 18\u201364 years of age with schizophrenia or bipolar disorder, who were dispensed an antipsychotic medication and had a diabetes screening test during the measurement year.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/cardiovascular-monitoring-for-people-with-cardiovascular-disease-and-schizophrenia-smc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC) - NCQA\" \/>\n<meta property=\"og:description\" content=\"Assesses adults 18\u201364 years of age with schizophrenia or bipolar disorder, who were dispensed an antipsychotic medication and had a diabetes screening test during the measurement year.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/cardiovascular-monitoring-for-people-with-cardiovascular-disease-and-schizophrenia-smc\/\" \/>\n<meta property=\"og:site_name\" content=\"NCQA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/NCQA.org\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-30T12:06:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2021\/04\/NCQA_cmyk_tag.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@NCQA\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/cardiovascular-monitoring-for-people-with-cardiovascular-disease-and-schizophrenia-smc\/\",\"url\":\"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/cardiovascular-monitoring-for-people-with-cardiovascular-disease-and-schizophrenia-smc\/\",\"name\":\"Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC) - NCQA\",\"isPartOf\":{\"@id\":\"https:\/\/www.ncqa.org\/#website\"},\"datePublished\":\"2025-08-01T11:00:36+00:00\",\"dateModified\":\"2026-01-30T12:06:54+00:00\",\"description\":\"Assesses adults 18\u201364 years of age with schizophrenia or bipolar disorder, who were dispensed an antipsychotic medication and had a diabetes screening test during the measurement year.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/cardiovascular-monitoring-for-people-with-cardiovascular-disease-and-schizophrenia-smc\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/cardiovascular-monitoring-for-people-with-cardiovascular-disease-and-schizophrenia-smc\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/cardiovascular-monitoring-for-people-with-cardiovascular-disease-and-schizophrenia-smc\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ncqa.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Report Cards\",\"item\":\"https:\/\/www.ncqa.org\/report-cards\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Health Plans\",\"item\":\"https:\/\/www.ncqa.org\/report-cards\/health-plans\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"State of Health Care Quality Report\",\"item\":\"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/\"},{\"@type\":\"ListItem\",\"position\":5,\"name\":\"Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ncqa.org\/#website\",\"url\":\"https:\/\/www.ncqa.org\/\",\"name\":\"NCQA\",\"description\":\"Measuring quality. Improving health care.\",\"publisher\":{\"@id\":\"https:\/\/www.ncqa.org\/#organization\"},\"alternateName\":\"National Committee for Quality Assurance\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ncqa.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ncqa.org\/#organization\",\"name\":\"NCQA\",\"alternateName\":\"National Committee for Quality Assurance\",\"url\":\"https:\/\/www.ncqa.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ncqa.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ncqa.org\/wp-content\/uploads\/NCQA-Blog-Logo-Thumbnail.jpg\",\"contentUrl\":\"https:\/\/www.ncqa.org\/wp-content\/uploads\/NCQA-Blog-Logo-Thumbnail.jpg\",\"width\":876,\"height\":673,\"caption\":\"NCQA\"},\"image\":{\"@id\":\"https:\/\/www.ncqa.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/NCQA.org\",\"https:\/\/x.com\/NCQA\",\"https:\/\/www.instagram.com\/ncqa_dc\/\",\"https:\/\/www.youtube.com\/@NcqaOrg\",\"https:\/\/www.linkedin.com\/company\/ncqa\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC) - NCQA","description":"Assesses adults 18\u201364 years of age with schizophrenia or bipolar disorder, who were dispensed an antipsychotic medication and had a diabetes screening test during the measurement year.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/cardiovascular-monitoring-for-people-with-cardiovascular-disease-and-schizophrenia-smc\/","og_locale":"en_US","og_type":"article","og_title":"Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC) - NCQA","og_description":"Assesses adults 18\u201364 years of age with schizophrenia or bipolar disorder, who were dispensed an antipsychotic medication and had a diabetes screening test during the measurement year.","og_url":"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/cardiovascular-monitoring-for-people-with-cardiovascular-disease-and-schizophrenia-smc\/","og_site_name":"NCQA","article_publisher":"https:\/\/www.facebook.com\/NCQA.org","article_modified_time":"2026-01-30T12:06:54+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/www.ncqa.org\/wp-content\/uploads\/2021\/04\/NCQA_cmyk_tag.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@NCQA","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/cardiovascular-monitoring-for-people-with-cardiovascular-disease-and-schizophrenia-smc\/","url":"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/cardiovascular-monitoring-for-people-with-cardiovascular-disease-and-schizophrenia-smc\/","name":"Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC) - NCQA","isPartOf":{"@id":"https:\/\/www.ncqa.org\/#website"},"datePublished":"2025-08-01T11:00:36+00:00","dateModified":"2026-01-30T12:06:54+00:00","description":"Assesses adults 18\u201364 years of age with schizophrenia or bipolar disorder, who were dispensed an antipsychotic medication and had a diabetes screening test during the measurement year.","breadcrumb":{"@id":"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/cardiovascular-monitoring-for-people-with-cardiovascular-disease-and-schizophrenia-smc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/cardiovascular-monitoring-for-people-with-cardiovascular-disease-and-schizophrenia-smc\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/cardiovascular-monitoring-for-people-with-cardiovascular-disease-and-schizophrenia-smc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ncqa.org\/"},{"@type":"ListItem","position":2,"name":"Report Cards","item":"https:\/\/www.ncqa.org\/report-cards\/"},{"@type":"ListItem","position":3,"name":"Health Plans","item":"https:\/\/www.ncqa.org\/report-cards\/health-plans\/"},{"@type":"ListItem","position":4,"name":"State of Health Care Quality Report","item":"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/"},{"@type":"ListItem","position":5,"name":"Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)"}]},{"@type":"WebSite","@id":"https:\/\/www.ncqa.org\/#website","url":"https:\/\/www.ncqa.org\/","name":"NCQA","description":"Measuring quality. Improving health care.","publisher":{"@id":"https:\/\/www.ncqa.org\/#organization"},"alternateName":"National Committee for Quality Assurance","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ncqa.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ncqa.org\/#organization","name":"NCQA","alternateName":"National Committee for Quality Assurance","url":"https:\/\/www.ncqa.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ncqa.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.ncqa.org\/wp-content\/uploads\/NCQA-Blog-Logo-Thumbnail.jpg","contentUrl":"https:\/\/www.ncqa.org\/wp-content\/uploads\/NCQA-Blog-Logo-Thumbnail.jpg","width":876,"height":673,"caption":"NCQA"},"image":{"@id":"https:\/\/www.ncqa.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/NCQA.org","https:\/\/x.com\/NCQA","https:\/\/www.instagram.com\/ncqa_dc\/","https:\/\/www.youtube.com\/@NcqaOrg","https:\/\/www.linkedin.com\/company\/ncqa\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/pages\/40931","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/users\/45"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/comments?post=40931"}],"version-history":[{"count":1,"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/pages\/40931\/revisions"}],"predecessor-version":[{"id":49458,"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/pages\/40931\/revisions\/49458"}],"up":[{"embeddable":true,"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/pages\/733"}],"wp:attachment":[{"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/media?parent=40931"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}